Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO’s Expanded Essential Drugs List Includes High-Priced Anticancers & Immunomodulators

Executive Summary

The World Health Organization has published its latest list of essential medicines, with a number of expensive drugs for cancers and autoimmune disorders figuring for the first time. The organization says that all patients should have access to life-saving medicines regardless of their ability to pay, but the pharmaceutical industry says this should be done with caution to avoid undermining innovation.

You may also be interested in...



Ambitious WHO Plan To Help 50 Nations Improve Regulatory Capacity

The World Health Organization has drawn up a plan to help member states build effective and efficient regulatory systems in order to deliver quality-assured medical products for all.

EU Countries Offered Funding To Contribute to African Regulatory Strengthening

Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.

National Drug Stockpiles Create ‘False Sense Of Security’

The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel